A case report of immune-related pneumonitis after combined treatment of non small cell lung cancer

Immunotherapy is the most promising method in the treatment of lung cancer, especially in connection with the rapidly growing development of monoclonal antibodies aimed at inhibiting immune checkpoints: anti-CTLA-4, anti-PD-1, anti-PD-L1. Classic immuno-mediated adverse events that occur with this method of treatment can affect several organs, including the lungs. Pneumonitis is a potentially life-threatening complication and often requires rapid treatment with high doses of corticosteroids and antibacterial drugs.
We present the case of a 67-year-old patient with primary multiple malignant tumors of the larynx and left lung after combined treatment and incomplete treatment with Nivolumab, complicated by immuno-mediated pneumonitis.
This report highlights the importance of treating patients with contraindications to chemotherapy when specific antitumor treatment is required, as well as timely detection of a rare but dangerous adverse event: immuno-mediated pneumonitis that occurs during treatment with immune checkpoint inhibitors.
Thus, knowing the frequency of adverse events when using PD-1 and PD-L1 inhibitors, as well as the possible presence of comorbidities in patients, will make it easier for doctors to make informed decisions in the treatment of patients, and understanding the interaction of the tumor and the immune system will help determine the best predictors of response and further improve the results of treatment of patients with NSCLC.

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590.

2. Bareschino M.A., Schettino C., Rossi A., Maione P., Sacco P.C., Zeppa R., Gridelli C. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122–133. doi: 10.3978/j.issn.2072-1439.2010.12.08.

3. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wuet Y.L. et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809– 1818. doi: 10.1016/S0140-6736(08)61758-4.

4. Iacono D., Chiari R., Metro G., Bennati C., Bellezza G., Cenci M. et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87(3):211–219. doi: 10.1016/j.lungcan.2014.12.017.

5. Asahina H., Sekine I., Horinouchi H., Nokihara H., Yamamoto N., Kubota K. et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer. 2012;13(1):39–43. doi: 10.1016/j.cllc.2011.06.008.

6. Stinchcombe T.E. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer. Curr Treat Options Oncol. 2016;17(4):18. doi: 10.1007/s11864-016-0394-4.

7. Doroshow D.B., Sanmamed M.F., Hastings K., Politi K., Rimm D.L., Chen L. et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. Clin Cancer Res. 2019;25(15):4592–4602. doi: 10.1158/1078-0432.CCR-18-1538.

8. Brahmer J., Reckamp K.L., Baas P., Crinò L., Eberhardt W.E., Poddubskaya E. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell NonSmall-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–135. doi: 10.1056/NEJMoa1504627.

9. Borghaei H., Paz-Ares L., Horn L., Spigel D.R., Steins M., Ready N.E. et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi: 10.1056/NEJMoa1507643.

10. Postow M.A. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. 2015;76–83. doi: 10.14694/EdBook_AM.2015.35.76.

11. Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., Angelis F.D. et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–2092. doi: 10.1056/NEJMoa1801005.

12. Vokes E.E., Ready N., Felip E., Horn L., Burgio M.A., Antonia S.J. et al. Nivolumab versus docetaxel in previously treated advanced non-smallcell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. doi: 10.1093/annonc/mdy041.

13. Yasuda K., Tanaka T., Ishihara S., Otani K., Nishikawa T., Kiyomatsu T. et al. Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surg Case Rep. 2017;3(1):94. doi: 10.1186/s40792-017-0370-7.

14. Guan M., Zhou Y.P., Sun J.L., Chen S.C. Adverse events of monoclonal antibodies used for cancer therapy. Biomed Res Int. 2015;2015:428169. doi: 10.1155/2015/428169.

15. Weber J.S., Yang J.C., Atkins M.B., Disis M.L. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092–2099. doi: 10.1200/JCO.2014.60.0379.

16. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690.

17. Nishino M., Giobbie-Hurder A., Hatabu H., Ramaiya N.H., Hodi F.S. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607–1616. doi: 10.1001/jamaoncol.2016.2453.

18. Wang Y., Zhou S., Yang F., Qi X., Wang X., Guan X. et al. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019;5(7):1008–1019. doi: 10.1001/jamaoncol.2019.0393.

19. Toh C.K., Wong E.H., Lim W.T., Leong S.S., Fong K.M., Wee J. et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126(6):1750–1756. doi: 10.1378/chest.126.6.1750.

20. Bouros D., Hatzakis K., Labrakis H., Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 2002;121(4):1278–1289. doi: 10.1378/chest.121.4.1278.

21. De Velasco G., Je Y., Bossé D., Awad M.M., Ott P.A., Moreira R.B. et al. Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients [published correction appears in Cancer Immunol Res. 2018;6(4):498–499]. Cancer Immunol Res. 2017;5(4):312–318. doi: 10.1158/2326-6066.CIR-16-0237.

22. Naidoo J., Wang X., Woo K.M., Iyriboz T., Halpenny D., Cunningham J. et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/ Programmed Death Ligand 1 Therapy [published correction appears in J Clin Oncol. 2017;35(22):2590]. J Clin Oncol. 2017;35(7):709–717. doi: 10.1200/JCO.2016.68.2005.

23. Xia L., Liu Y., Wang Y. PD-1/PD-L1 Blockade Therapy in Advanced NonSmall-Cell Lung Cancer: Current Status and Future Directions. Oncologist. 2019;24(1):31–41. doi: 10.1634/theoncologist.2019-IO-S1-s05.

24. Shao J., Wang C., Ren P., Jiang Y., Tian P., Li W. Treatment- and immunerelated adverse events of immune checkpoint inhibitors in advanced lung cancer. Biosci Rep. 2020;40(5):BSR20192347. doi: 10.1042/BSR20192347.

25. Engel-Nitz N.M., Johnson M.P., Bunner S.H., Ryan K.J. Real-World Costs of Adverse Events in First-Line Treatment of Metastatic Non-Small Cell Lung Cancer. J Manag Care Spec Pharm. 2020;26(6):729–740. doi: 10.18553/jmcp.2020.26.6.729.